Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence.

MLA

Tanaka, Masumi, et al. “Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-Stage Breast Cancer Recurrence.” Anticancer Research, vol. 42, no. 4, Apr. 2022, pp. 2079–85. EBSCOhost, https://doi.org/10.21873/anticanres.15689.

APA

Tanaka, M., Yamashita, S.-I., Yoshinaga, Y., Enomoto, Y., Nohara, Y., Ono, S., Nabeshima, K., Iwasaki, A., & Sato, T. (2022). Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence. Anticancer Research, 42(4), 2079–2085. https://doi.org/10.21873/anticanres.15689

Chicago

Tanaka, Masumi, Shin-Ichi Yamashita, Yasuteru Yoshinaga, Yasuko Enomoto, Yuki Nohara, Syuko Ono, Kazuki Nabeshima, Akinori Iwasaki, and Toshihiko Sato. 2022. “Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-Stage Breast Cancer Recurrence.” Anticancer Research 42 (4): 2079–85. doi:10.21873/anticanres.15689.